pine intake in therapeutic doses by urine analysis: evaluation of two immuno techniques and modification for improved performance. Clin Chem 1992;38:271-6.
In recent years, the location where moat clinical chemistry analytical methodologies are developed has changed. Most immunoassays currently in use in clinical laboratories have been developed by the diagnostic industry, rather than the clinical laboratory, and are purchased in "kit" form. The reasons for this trend are numerous and relate largely to the growing complexity of immunoassay development. A cursory review of the publication patterns in this Journal reveals some of this trend. Just 15 years ago (in the first six issues of the 1977 volume of Clinical Chemistry) -55% of the papers could be classified as descriptions of the development of novel analytical methods written by nonindustry-based authors. In the first six issues of 1991, this proportion had decreased to 38%.
Many clinical chemists, especially those in hospital clinical laboratories, focus considerable attention on the evaluation and modification of commercially developed assay kits. Adaptation of kits to new analytical platforms has often led to such modifications, and some authors have described modifications of commercial kits either to decrease operating costs or to tailor assay performance to their needs. In therapeutic drug monitoring and toxicology, method modification has been an especially common practice. The first publication of the adaptation of a commercial immunoassay kit for drug screening to an open clinical chemistry analyzer was in 1975 (1). Subsequently, numerous publications described the adaptation of Syva's EMIT technology to various analytical systems. Some of these adaptations required modification of the kits, either by simple dilution (2) or by the actual modification of the formulation (3).
Many immunoassay kits, especially those for radioimmunoassay, are intended for use on general purpose laboratory equipment. Others-most often nonisotopic immunoassays-are designed for use with a specific manufacturer's equipment. Analytical systems, i.e., analyzers and their associated reagents and disposables, are the most difficult to modify, especially if optimization of the system as a whole is to be maintained. Abbott's TDx system illustrates this very well. During research and development of a particular assay, the reagent systems and the analyzer are optimized concordantly, resulting in a system that is robust and stable. Modifications to either the reagent or the analyzer can "de-optimize" the whole system and make it impossible for the system to meet the manufacturer's claims. Analytical systems that can perform multiple assays add an additional layer of complexity. Manufacturers take great pains to mmimi7.e or eliminate sample-to-sample and reagent-to-reagent interactions on these analyzers, often by using particular formulation designs or by incorporating specific steps in the way that the analyzer processes the assays.
In the more heavily regulated environment of the 1990s, a system's ability to meet the manufacturer's claims will become even more important than it has been. The claims that a manufacturer makes in labeling and package inserts are perhaps the most carefully scrutinized components of a company's submission to the Food and Drug Administration (FDA), precisely because they are the manufacturer's only consistent way of describing to its customers what the capabilities and limitations of the system really are.
The EC 3.2.1.31) to increase the assays' ability to detect additional species of benzodiazepines and to increase the sensitivity (lower the detection limit) of the assays to benzodiazepines already known to react in the systems.
After enzyme treatment of the urine samples, the authors saw relative increases in fluorescence polarization response of the TDx ranging from 10% (for chlordiazepoxide) to 488% (for lorazepam). The conclusions are, of course, consistent with expectations. Lorazepam is primarily excreted as a p-glucuronide conjugate, and the fluorescence polarization immunoassay responds only moderately to lorazepam (lorazepam generates 40% of the response of the calibrator, nordiazepam). Hydrolyzing lorazepam conjugates in the samples substantially increases the concentration of free lorazepam, presumably enough to shift the concentration in patients' samples above the detection threshold of the system. Notably, the authors also recommended lowering the detection threshold of the assay, to 0.1 ng/L from the 0.2 ng/L suggested by Abbott.
What price could the proponents of this approach pay? Does lowering the cutoff increase the number of "false- detection after enzymic hydrolysis. Could other compounds in the urine be hydrolyzed by this procedure, and could these hydrolysis products cross-react in the assay? Additionally, the potential for other adverse effects was not addressed by the authors. If other tests are run on the same sample (e.g., an assay for opiates), would the modification have an impact on the performance of those assays? Is there any potential for sample-to-sample or reagent-to-reagent interaction that is caused by or amplified by the presence of the enzyme in the samples?
The work of Beck et al., although laudable in its goals, leaves several questions unanswered.
Admittedly, manufacturers of assay systems cannot always include the performance requirements of all potential users in their design goals. On the other hand, the users of these modified kits often cannot undertake the extent of performance validation that is common practice in the diagnostic industry today. In the case exemplified by Beck et al., both the analytical sensitivity and specificity of the kit were modified: under the CLIA '88 regulations, extensive performance evaluation would need to be performed by every user of the modified procedure, not just the investigators originally describing the modification in the literature.
Scientists in industry and in the clinical setting need to work together more closely to promote the development of new and better diagnostic assays. The Unilateral modification of carefully developed and optimized assay systems can lead to a host of system performance failures that invalidate many of the performance claims made by the system's manufacturer. Users of such modified procedures need to be aware of the additional validation work required and of the ultimate liability for adverse clinical events directly attributable to the modification.
